AAP and apalutamide may improve outcomes, compared with bicalutamide, in a subgroup of patients with prostate cancer receiving ADT and salvage radiation after radical prostatectomy, according to researchers.
Rucaparib improves radiographic progression-free survival when compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer, according to results from the TRITON3 trial.
Findings from a systematic review and meta-analysis showed the relationship between gout and venous thromboembolism.
Renal cell carcinoma patients with NF2 driver mutations often present with metastatic disease and have worse survival outcomes, research suggests.
Patients receiving first-line pembrolizumab-axitinib for metastatic renal cell carcinoma have lower health care resource utilization than patients receiving ipilimumab-nivolumab.
Following the 2013 AUA guidelines on surveillance after partial nephrectomy can improve metastasis-free survival, a study suggests.
Among patients with renal cell carcinoma, clinical presentation, extent of disease, and germline and somatic alterations differ according to genetic ancestry.
Sarcopenic patients with metastatic renal cell carcinoma have distinct bacterial populations that express metabolic pathways associated with a catabolic state.
Patients hospitalized with COVID-19 receiving supplemental oxygen had similar mortality outcomes with high- vs standard-dose dexamethasone, but evidence suggests higher dexamethasone doses may be associated with adverse outcomes. These study results were presented at IDWeek 2022, held from October 19 to 23, in Washington, DC. Anti-inflammatory agents, such as dexamethasone, are standard treatment for COVID-19…
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
